Consumer News: Stop using AILUKI cordless drills, safety regulators warn

If youve got a 15-gallon tank, thats $3.75 off

• Prime members get 25/gal off on Fridays through the holidays at select BP/Amoco/ampm stations
• Link Prime to the fuel perk once, then enter your phone number (or use the app) at the pump on Fridays
• Valid at participating stations, generally one use per Fridaynice small savings on a typical fill-up

What it is andhow it works

If youre doing any driving to see family this season, Amazon quietly rolled out a nice little perk for Prime members that will save you money at the gas pump. Every Friday between now and Christmas youll save 25 per gallon at thousands of gas stations.

Its a limited-time holiday thing, and yes, it stacks on top of the everyday Prime fuel perk. The fine print is very user friendly and setup only takes a couple minutes.

Whats the discount? 25/gal discount every Friday now through December 26, 2025 at participating stations. Its a seasonal 15/gal Friday bonus that stacks with the regular 10/gal Prime fuel savings.

Where does it work? BP, Amoco, and participating AmPm locations (about 7,500 nationwide).

What do I need? An Earnify account via the Earnify app (BPs fuel rewards). You link it once to your Amazon account, then youre set.

How to turn it on (takes a couple minutes)

Go to Amazons Prime fuel savings page and tap the Activate Now button and follow the prompts to link your Prime account to Earnify (BPs rewards).

If you dont already have Earnify, youll create an account during the process.

Then on any Friday, pull into a BP / Amoco / AmPm station that participates. The Earnify app can show you nearby stations and give you directions which is handy.

Then when you get to pump, redeem by doing one of the following:

• Enter your linked phone number at the pump.
• Or use the Earnify app at the pump to verify (youll select your station/pump)

The 25/gal discount will apply automatically.

What to watch for

One use per Friday: Amazons offer page specifies the 25 Friday discount is valid one time each Friday during the promo window (Oct 17Dec 26, 2025). Plan your fill-ups accordingly.

Participating stations only: Not every BP/Amoco/ampm location participates. Check the Earnify app first so you dont pull up to the wrong pump.

Does it add up to real money?

If youve got a 15-gallon tank, thats $3.75 off per Friday fill-up with the holiday 25 discount.

So if you figure two Friday departure road-trips in a month, where you fill up on the way out of town, youre shaving $7.50 off what youd normally pay. Nothing life-changing, but not nothing either.

Why is Amazon doing this?

In recent months, Prime benefits have been creeping into the real world with things like fuel discounts, grocery perks, and even prescription savings.

Its clearly a push to give Prime subscribers value beyond just shipping and streaming perks that consumers are already familiar with.

For BP, it gets more traffic to their stations along with new sign-ups for Earnify, so its definitely a win-win.

Plus, it helps Amazon keeps Prime top of mind for consumers during a pricey holiday travel season.

Officials warn of devastating impact if SNAP payments stop

Some once-hot Florida markets are close behind

By Mark Huffman of ConsumerAffairs

• Austin tops the list of the strongest buyers markets, with 130% more home sellers than buyers in September, according to Redfin.

• Florida metros dominate the list, with Fort Lauderdale, West Palm Beach, and Miami all ranking in the top five.

• Nationwide, sellers outnumbered buyers by 36.7%, giving home shoppers more negotiating power than at nearly any point in the past decade.

Remember when a house in Austin or Miami could go on the market and sell in a day, usually for more than the list price? Those days are over, according to a new new housing report from real estate brokerage Redfin.

According to the report, Austin has become the nations most favorable market for homebuyers, with 130% more sellers than buyers in September. The oversupply of homes means buyers in Austin, and in many Sun Belt metros, are finding themselves with rare bargaining power.

Following Austin are Fort Lauderdale, West Palm Beach, and Miami in Florida, along with Nashville rounding out the top five. In total, eight of the ten strongest buyers markets are in Texas or Florida, two states that have seen a construction boom in recent years.

Nationally, sellers outnumbered buyers by 36.7%, nearly matching the record gap of 36.9% recorded in June 2025. The imbalance means that homes are staying on the market longer and sellers are increasingly willing to negotiate on price and closing costs.

According to Redfin, these are the housing markets that have changed the most to favor buyers:

The Austin market

Austins shift reflects a combination of soaring housing supply and falling rent prices, which have pushed many would-be buyers to rent instead.

Rents have gone down so much in Austin that a lot of people are opting to rent instead of buy, said Andrew Vallejo, a Redfin Premier agent in Austin. If a $500,000 home costs about $4,000 a month to own, but you can rent it for $2,500, the math just doesnt add up for many buyers.

Some sellers are finding the new reality sobering. Vallejo recalled a homeowner who bought a property for $420,000 in 2022 but would be lucky to sell for $250,000 today. Its a tough conversation, he said, but the good news is that lower prices are finally opening doors for first-time buyers.

Nationwide, the number of active home sellers had been rising, until recently. Now, some homeowners are pulling their listings rather than accept reduced prices in a sluggish market.

In Miami, for instance, the gap between sellers and buyers has narrowed from 165% a year ago to 112% this September, as some frustrated sellers withdraw their listings and rent out properties instead.

Miamis housing market is at a standstill, said Ozzie Linares, a Redfin agent. Many sellers just dont want to face the reality that their homes arent worth what they were two years ago.

Where sellers still have the upper hand

While most of the nation favors buyers, five major metro areas remain sellers markets, primarily in the Northeast and Midwest. Newark, N.J., leads with roughly 42% fewer sellers than buyers, followed by Nassau County, N.Y.; Montgomery County, Pa.; New Brunswick, N.J.; and Cleveland, Ohio.

These markets tend to have limited housing inventory and slower new construction, keeping demand high despite rising borrowing costs.

Compared to a year ago, Austin and Denver have experienced the largest swings toward buyer-friendly conditions. Austins buyer-seller gap widened by 49 percentage points year over year, while Denvers grew by 46 points.

On the flip side, Miami and Kansas City are among the metros moving back toward balance, though most still lean toward buyers.

The dramatic fall comes after a series of record highs

By Mark Huffman of ConsumerAffairs

• Gold suffered its largest one-day percentage drop in over a decade, sliding around 6 % on Tuesday after hitting a record high the day before.

• Silver plunged even more dramatically, falling more than 8 % in the same session, as momentum from its recent rally abruptly reversed.

• Key catalysts include profit-taking after the sharp run-up, strengthening of the U.S. dollar, easing safe-haven demand and signs of improved economic sentiment.

The precious-metals market lurched backward on Tuesday as previously surging prices for gold and silver came under sharp pressure, marking a dramatic reversal in what had been a banner year for bullion.

But the sell-off followed a series of massive gains, which had pushed gold and silver prices to unseen levels. Walls of selling flooded the market after gold vaulted to a new all-time high on Monday, only to suddenly retreat. Gold continued to fall on Wednesday, with the price down 1%.

On Tuesday, spot gold dropped to approximately U.S. $4,120 per troy ounce, from its near-US $4,400 peak just a day earlier, the most significant one-day percentage decline since 2013. Silver, meanwhile, tumbled to around US $48.40 per ounce, down more than 8 % from recent highs.
Several related factors appear to have triggered the sharp reversal:

1. Profit-taking and overbought positioning After months of steady gains, bullion markets were flush with speculative momentum. As one analyst put it, gold had become frothy at elevated valuation levels.

2. A firmer U.S. dollar and rising yields A stronger dollar tends to make dollar-priced metals more expensive for foreign buyers, reducing demand, while higher bond yields raise the opportunity cost of holding non-yielding assets like gold and silver.

3. Signs of easing safe-haven demand The surge in gold earlier this year was fueled in part by geopolitical uncertainty, inflation fears and global debt concerns. With some of those fear factors appearing to moderate, investors rotated away from bullion.

4. Technical correction after record highs Having reached unprecedented levels, the markets appeared ripe for a pull-back, and analysts flagged the drop as a likely healthy retracement rather than a structural reversal.

Market ripple effects

The move didnt stay confined to gold itself. Shares of gold-mining companies, leveraged to gold prices, slid sharply with some names down around 9 %. The broader commodities complex also felt pressure as the metal-price backdrop shifted.

Despite Tuesdays dramatic drop, many analysts caution against reading the move as an end to the bullish thesis for precious metals. The long-term drivers such as inflation risk, fiscal stress and monetary-policy uncertainty remain intact.

That said, the correction underscores that timing and context matter: entering at the top of a momentum wave carries risk.

It dramatically improves survival in men whose cancer returns

By Mark Huffman of ConsumerAffairs

• Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer.

• The international study, published in The New England Journal of Medicine, involved more than 1,000 patients across 17 countries.

• Experts say the results could establish the combination as a new standard of care for aggressive prostate cancer that returns after surgery or radiation.

A new drug treatment has shown remarkable promise for men whose prostate cancer returns after initial treatment, cutting the risk of death by more than 40% compared with existing therapies.

The findings, published in The New England Journal of Medicine and presented at the European Society for Medical Oncology Congress (ESMO) in Berlin, could reshape how physicians treat high-risk prostate cancer that no longer responds to traditional methods.

Researchers found that adding enzalutamide, a hormone-blocking medication, to standard hormone therapy significantly improved long-term survival in men with biochemically recurrent prostate cancer, a form of the disease that resurfaces after surgery or radiation therapy and is often a precursor to metastatic cancer.

After initial treatment, some patients see their prostate cancer come back in an aggressive way and are at risk for their disease to spread quickly, said Dr. Stephen Freedland, co-principal investigator and director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Cancer.

Hormone therapy, which is what weve been offering patients for 30 years, has not improved survival and neither has anything else. That makes these findings a real game changer.

A global effort and clear result

The trial enrolled more than 1,000 men from 244 sites across 17 countries, all diagnosed with high-risk biochemically recurrent prostate cancer. After initial therapy, these patients experienced rapid increases in levels of prostate-specific antigen (PSA), a protein that signals potential cancer recurrence and spread.

Participants were randomly assigned to receive either hormone therapy alone, enzalutamide alone, or a combination of both. After eight years of follow-up, those who received the combination treatment had a 40.3% lower risk of death compared with patients in the other groups.

We know these patients are at high risk of developing metastatic disease and dying of their cancer unless we offer a meaningful treatment option, Freedland said.

Enzalutamide, already approved by the U.S. Food and Drug Administration and included in National Comprehensive Cancer Network (NCCN) guidelines for other stages of prostate cancer, could soon see its use expanded based on these results. Freedland said the new data are likely to solidify the drugs role as a standard of care for men with high-risk recurrent disease.

This clinical trial, one of many that Cedars-Sinai Cancer has offered to its patients, is an example of the translational work being done by our physician-scientists, said Dr. Robert Figlin, interim director of Cedars-Sinai Cancer. The result will be improved treatment and better outcomes for patients everywhere.